1	T cell Homeostatic Imbalance in Placentae from Women Infected with HIV in the absence of
2	Vertical Transmission.
3	
4	Nadia M. Ikumi ¹ , Komala Pillay ^{3,4} , Tamara Tilburgs ^{5,6} , Thokozile R. Malaba ⁷ , Sonwabile Dzanibe ¹
5	Elizabeth Ann L Enninga ⁸ , Rana Chakraborty ^{8,9,10} , Mohammed Lamorde ¹¹ , Landon Myer ⁷ , Saye
6	Khoo ¹² , Heather B Jaspan ¹ and Clive M. Gray ^{1,2,3*} , for the DolPHIN-2 Study Group
7	
8	¹ Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape
9	Town, South Africa.
10	² Department of Pathology, University of Cape Town, Cape Town, South Africa
11	³ National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa
12	⁴ Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape Town,
13	South Africa
14	⁵ Division of Immunobiology, Center for Inflammation and Tolerance, Cincinnati Children's Hospital,
15	Cincinnati OH 45229, USA
16	⁶ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH 45229, USA
17	⁷ Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University
18	of Cape Town, Cape Town, South Africa
19	⁸ Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905
20	⁹ Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine and Science,
21	Minnesota, USA
22	¹⁰ Department of Immunology, Mayo Clinic, Rochester, MN 55905
23	¹¹ Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
24	¹² Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK; Royal Liverpool and
25	Broadgreen University Hospitals NHS Trust, Liverpool, UK
26	Running title: Altered T cell immunity during HIV in the placenta

2

0	-
2	1

28 Conflict of interest statement

29 The authors have declared that no conflict of interest exists.

30

31 *Corresponding Author

- 32 Clive M Gray, Division of Immunology, Institute of Infectious Disease and Molecular Medicine,
- 33 Falmouth Building, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory,
- 34 Cape Town, South Africa, 7925; Tel: +27 21 406 6616; Email: clive.gray@uct.ac.za

- 36 Word count: Abstract: 200 words, Lay abstract: 192 words; Main text 3490; 47 references; 5 Figures
- and 2 Tables; supplementary figures <25MB.

ABSTRACT

39	Background: Implementation of Option B+ antiretroviral therapy (ART) has significantly lowered
40	vertical transmission rates but has also increased numbers of HIV-exposed uninfected children
41	(HEU), who remain vulnerable to morbidities. Here, we investigated whether altered immune status
42	in HEU originates in the placenta.
43	Methods: We analyzed T cells from term placentae decidua and villous tissue and paired cord blood
44	from pregnant women living with HIV (PWLWH) who initiated ART late in pregnancy (n=21) with HIV
45	negative controls (n=9).
46	Results: Placentae from PWLWH showed inverted CD4:CD8 ratios and higher proportions of tissue
47	resident CD8+ T cells in villous tissue relative to control placentae. CD8+ T cells in the fetal
48	capillaries, which were of fetal origin, positively correlated with maternal plasma viraemia prior to
49	ART initiation, implying that imbalanced T cells persisted throughout pregnancy. Additionally, the
50	expanded memory differentiation of CD8+ T cells was confined to the fetal placental compartment
51	and cord blood, but was not observed in the maternal decidua.
52	Conclusion: T cell homeostatic imbalance in the blood circulation of PWLWH is reflected in the
53	placenta. The placenta may be a causal link between HIV-induced maternal immune changes during
54	gestation and altered immunity in newborn infants in the absence of vertical transmission.
55	
56	Keywords: T cells, placenta, HIV, prolonged exposure, placenta pathology
57	

59 Lay Summary

60 The effective prevention of HIV transmission during pregnancy with the rollout of antiretroviral 61 therapy (ART) has resulted in increased numbers of HIV-exposed uninfected children (HEU). These 62 children are vulnerable to infections and health problems and they have altered cellular immune 63 systems at birth. We investigated whether these immune alterations may originate in the placenta, 64 as this fetal organ maintains life during pregnancy. Do immune alterations in the newborn child 65 originate in the placenta? After collecting placentae at term from pregnant women living with HIV 66 (PWLWH), who started ART in the third trimester (n=21) and from HIV negative controls (n=9), we 67 isolated T cells from dissected placental tissue and matching cord blood. Placentae from PWLWH 68 showed inverted CD4:CD8 ratios in the placenta and cord blood with higher numbers of CD8+ T cells 69 in the fetal part of the placenta. These CD8+ T cells mirrored events in the blood circulation of the 70 mother and the altered balance of T cell immunity in the PWLWH was reflected in the placenta. 71 Accordingly, the placenta may be a pivotal link between HIV-induced maternal immune changes and 72 altered immunity in new born infants in the absence of vertical transmission.

74 Background

In adults, HIV causes severe immune dysregulation, characterized by systemic depletion of CD4+ T cells, increased HIV-1 specific CD8+ T cells, inflammation and a progressive failure of the immune system[1–3]. Initiation of ART has been shown to augment HIV-specific CD4+ T cell responses, but normalization of the CD4:CD8 T cell ratio does not occur in a large proportion of HIV positive individuals[4]. In pregnant women living with HIV (PWLWH), pregnancy is not associated with HIV disease progression, although it has been associated with functional impairment of systemic effector T cells and an overall altered response against HIV control[5,6].

82

Placentae from PWLWH exhibit increased signs of inflammation and injury affecting maternal vasculature and circulation[7,8]. Although the maternal and fetal circulation within the placenta takes place in distinct compartments, there is evidence that maternal HIV infection impacts the fetal immune system. HIV-unexposed uninfected children (HUU) have an almost completely naïve T cell repertoire, but at birth HIV-exposed uninfected children (HEU) can have increased proportions of differentiated immune cells suggestive of antigen experience *in utero*[9,10]. This scenario raises the question of how HIV exposure *in utero* potentially creates perturbations of immunity in HEU[11,12].

90

91 In healthy human pregnancies, T cells in the placenta have been shown to constitute approximately 92 5-20% of total leukocytes in the decidua and this proportion increases up to over 40% at 93 term[13,14]. CD8+ T cells are the most abundant subset and are important in promoting embryo 94 implantation and providing immune protection against infection[15,16]. CD4+ T cell subsets have a 95 number of key roles including the establishment and maintenance of fetal-maternal (FM) 96 tolerance[17,18]. Fetus-specific CD4+ Tregs have been shown to migrate towards the FM interface 97 where they are enriched to guard against breakdown in FM tolerance[18]. In contrast, the presence 98 of CD8+ T cells in the villous tissue is often associated with villitis of unknown etiology (VUE), an

99 inflammatory state of the placenta characterized by the infiltration of maternal CD8+ T cells and

100 macrophages into the villi[19,20].

101	To test the hypothesis that maternal HIV infection is associated with disruption of T cell homeostasis
102	in the placenta and cord blood from HEU newborns, we examined term placentae from PWLWH
103	from a randomized trial in pregnant mothers initiating dolutegravir versus efavirenz-containing
104	therapy in the third trimester (DolPHIN-2: NCT03249181)[21], as well as pregnant women not living
105	with HIV (PWNLHIV), serving as controls. We show that placentae from PWLWH have inverted
106	CD4:CD8 ratios with higher CD8+ T cells in villous tissue relative to control placentae contributing to
107	T cell homeostatic imbalance in the placenta at birth.
100	

- 108
- 109
- 110

111 Methods

112 Cohort

We included 21 placentae with 9 paired cord blood samples from PWLWH and HEU and 9 placentae from PWNLHIV with 5 cord blood samples from HUU in this study. The PWLWH group was nested in the DolPHIN-2 study and recruited from the Gugulethu Community Health Centre, Cape Town[21]. HIV negative controls were enrolled nearby from the Khayelitsha Site B Midwife Obstetric Unit, Cape Town. All placentae were from term deliveries (>37 weeks' gestation).

119 Clinical Data collection

As part of DolPHIN-2, maternal systemic CD4 T cell counts were measured at ART initiation and plasma viral load (VL) copies were measured at screening, enrolment and ART initiation (visit 1), one week after ART initiation (visit 2), four weeks after ART initiation (visit 3), thirty-six weeks' GA (visit 4) and approximately ± 14 days after delivery (visit 5). The level of detection was 50 copies per ml[21].

125

126 Placenta and cord blood processing.

127 Cells were isolated from each placenta as previously described[22] and illustrated in Figure 1. 128 Placentae were collected in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and 129 penicillin/streptomycin at room temperature and processing was performed within six hours of 130 delivery. Briefly, each placenta was macroscopically inspected and dissected to obtain the decidua 131 parietalis, basalis and villous tissue. The sections were rinsed in phosphate-buffered saline (PBS) to 132 remove maternal blood. Enzymatic lymphocyte isolation was performed using 0.2% Collagenase I 133 and 0.02% DNAse I in RPMI 1640 at 37° C for 75 minutes. We then obtained the lymphocyte fraction 134 following Percoll density centrifugation at the 70-45% interface and incubated the cells with violet 135 amine reactive viability dye (VIVID, Thermofisher) according to manufacturer's instructions. The cells were then fixed using BD FACSTM lysing solution, cryopreserved in 90% FCS - 10% Dimethyl sulfoxide 136

8

(DMSO) and stored in liquid nitrogen until analysis. Cord blood mononuclear cells were isolated on
 Ficoll, fixed and cryopreserved in the same fashion as placental lymphocytes.

139

140 Placenta pathology

141 Placentae were fixed in 10% buffered formalin prior to histopathology examination at Red Cross 142 Memorial Children's Hospital, Cape Town, South Africa. Specimens were macroscopically examined 143 and samples from the umbilical cord, placental membranes and placental disk were obtained based 144 on the Amsterdam Placental Workshop Group Consensus Statement. [23] Briefly, four blocks were 145 prepared from each placenta; including a roll of the placental membranes, two cross sections of the 146 umbilical cord; and full-thickness sections of the placental parenchyma including one from the cord 147 insertion. Tissue sections were 3-5µm thick and were stained with haemotoxylin and eosin for 148 routine histological examination. Placentae were examined for features of prolonged meconium 149 exposure, chorioamnionitis with or without a maternal or fetal inflammatory response[24,25], 150 maternal vascular malperfusion (MVM) with decidual vasculopathy, and in the absence of decidual 151 vasculopathy, MVM was indicated by a small placenta for gestational age accompanied by at least 152 two villous changes (villous infarct, retroplacental haematoma, accelerated villous maturation or 153 distal villous hypoplasia). In the case of normal placenta weights for gestational age, at least 3-4 154 villous features were noted to be placed in the category of MVM[26]. Chronic deciduitis was defined 155 as abnormal infiltration of lymphocytes and plasma cells in the decidua[23].

156

157 Flow cytometry

Placental and cord blood cells were labeled with fluorochrome-conjugated monoclonal antibodies:
CD3 (Clone UCHT1), CD4 (Clone SK3), CD8 (Clone SK1), CD45RA (Clone H100), CD28 (Clone CD28.2),
CD14 (Clone MHCD1417) and CD45 (Clone MHCD4530). Samples were acquired using an LSR II flow
cytometer (BD Biosciences). Total CD4+ and CD8+ T cells were expressed as a proportion of CD3+ T
cells gated from the viable CD45+ CD14- cells (Supplementary Figure 1).

9

163 Immunohistochemistry

Formalin fixed paraffin embedded (FFPE) placenta tissue blocks were cut into 5 μM sections and stained with CD8 (Clone C8/144B), with tonsillar tissue serving as a control. Briefly, the slides were baked overnight at 56°C and rehydrated in xylene followed by varying concentrations of alcohol and then incubated in 3% hydrogen peroxide. Heat-mediated antigen retrieval was performed using an EDTA buffer (pH9). The slides were then incubated with 1% Bovine Serum Albumin (BSA) and stained with the primary antibody anti-CD8. The images were acquired on Zeiss Axioskop 200 upright Fluorescence microscope with an AxioCam high resolution colour (HRC) camera.

171

172 Fluorescence in situ hybridization (FISH)

173 We used five placental samples from male fetuses to identify the origin of the infiltrating 174 lymphocytes by FISH. Briefly, the slides were baked at 90°C for 15 minutes, deparaffinized in xylene, 175 dehydrated in 100% ethanol and then placed in 10mM Citric Acid (pH 6.0). The slides were then 176 dehydrated in varying concentrations of ethanol (70%, 85% and 100%). We then applied a working 177 solution of DXZ1/DYZ3 (Abbott Laboratories, Des Plaines, IL, USA) to the target areas, co-denatured 178 with a ThermoBrite (Abbott Laboratories) and hybridized overnight at 37°C. The slides were then 179 counter stained with 4'-6'-diamidino-2-phenylindole (DAPI) (Vector Laboratories). Tissue samples 180 were scanned and the qualitative result was determined based on observed signal patterns by 181 CytoVision (Leica Biosystems, Germany).

182

183 Statistics

All flow cytometry data were analyzed using FlowJo version 10 (Treestar). Statistical analyses were performed using Prism version 8 (Graphpad Software, San Diego, CA), STATA version 12.0 (Stata Corporation, College Station, Texas, USA) or R[27]. Immunohistochemistry tissue cell counts for each tissue section were obtained by counting the total number of positive CD8+ T cells on the immunostained slides (40x magnification) using Image J Fiji version 2 (WS Rasband, National

189	Institute of Health, Bethesda, MD). Tests of significance were performed using Mann-Whitney U and
190	Kruskal-Wallis tests for intergroup comparisons. The associations between cell proportions and viral
191	load or CD4 T cell counts were assessed using simple linear regression. All bivariate analyses
192	including maternal and infant characteristics, and placental pathology stratified by HIV-exposure or
193	by ART regimen were compared using Chi ² or Fisher's exact test and Wilcoxon rank-sum tests.
194	
195	Study approval
196	The study protocol, informed consent forms and all data collection tools were approved by the
197	University of Cape Town, Faculty of Health Sciences Research Ethics Committee. Written and signed
198	informed consent was obtained from all participants, including collection of placentae prior to study
199	inclusion.
200	
201	Results
202	Participant Characteristics.
202 203	Participant Characteristics. Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age
203	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age
203 204	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA)
203 204 205	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWLWH were more likely to be multigravida
203 204 205 206	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWLWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNLHIV and 39 weeks in the PWLWH (p=0.03)
203 204 205 206 207	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWLWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNLHIV and 39 weeks in the PWLWH (p=0.03) and there was a tendency toward lower birthweight in HEU (p=0.07). Among the 21 PWLWH, 16
 203 204 205 206 207 208 	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWLWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNLHIV and 39 weeks in the PWLWH (p=0.03) and there was a tendency toward lower birthweight in HEU (p=0.07). Among the 21 PWLWH, 16 (76.2%) were randomised to receive efavirenz (EFV + TDF + 3TC) and 5 (23.8%), dolutegravir (DTG +
203 204 205 206 207 208 209	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWLWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNLHIV and 39 weeks in the PWLWH (p=0.03) and there was a tendency toward lower birthweight in HEU (p=0.07). Among the 21 PWLWH, 16 (76.2%) were randomised to receive efavirenz (EFV + TDF + 3TC) and 5 (23.8%), dolutegravir (DTG + TDF + 3TC), shown in Supplementary Table 1. Median CD4 count at ART initiation was 358 cells/mm ³
 203 204 205 206 207 208 209 210 	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWLWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNLHIV and 39 weeks in the PWLWH (p=0.03) and there was a tendency toward lower birthweight in HEU (p=0.07). Among the 21 PWLWH, 16 (76.2%) were randomised to receive efavirenz (EFV + TDF + 3TC) and 5 (23.8%), dolutegravir (DTG + TDF + 3TC), shown in Supplementary Table 1. Median CD4 count at ART initiation was 358 cells/mm ³ (IQR 278 – 477), with no difference between ART groups (Supplementary Table 2). The median VL at
203 204 205 206 207 208 209 210 211	Maternal and newborn infant characteristics are shown in Table 1. No differences in maternal age were noted between PWNLHIV and PWLWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWLWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNLHIV and 39 weeks in the PWLWH (p=0.03) and there was a tendency toward lower birthweight in HEU (p=0.07). Among the 21 PWLWH, 16 (76.2%) were randomised to receive efavirenz (EFV + TDF + 3TC) and 5 (23.8%), dolutegravir (DTG + TDF + 3TC), shown in Supplementary Table 1. Median CD4 count at ART initiation was 358 cells/mm ³ (IQR 278 – 477), with no difference between ART groups (Supplementary Table 2). The median VL at ART initiation was 4.54 log ₁₀ RNA copies/ml (IQR 3.85 – 4.80) in the EFV group versus 3.83 log ₁₀ RNA

11

log₁₀ RNA copies/ml) at 4 weeks versus 2 weeks after delivery (Supplementary Table 2 and [21]). For
the purposes of this study, we combined the placentae from two ART groups, as there were only 5
collected from the DTG arm.

218

219 Placental weight is altered by HIV.

220 Table 2 shows placenta characteristics and pathology stratified by HIV status. PWNLHIV had 221 significantly larger placentae (468g, IQR 426 - 533) compared to the PWLWH (394g, IQR 343 - 469; 222 p=0.02), with 38% of placentae in PWLWH being $<10^{th}$ percentile weight-for-gestation compared to 223 0% in PWNLHIV. These differences were also reflected the in the fetal-placental (FP) ratios, where all 224 cases with FP ratios > 90th percentile were in the PWLWH cases (p=0.02). Placental histopathology 225 identified 2 cases (9.5%) of chronic deciduitis and 6 cases (28.6%) of MVM, all in the PWLWH. There 226 were no significant differences in the incidence of meconium exposure and chorioamnionitis 227 between PWLWH and PWNLHIV, and there was no evidence of villitis of unknown etiology (VUE) in 228 any of the placentae. There were no significant differences in the placental weight, FP ratio and 229 placental pathology between the two ART groups (Supplementary Table 3).

230

HIV infection during pregnancy alters placental CD4+ and CD8+ T cell proportions.

232 Figure 2A shows significantly lower proportions of CD4+T cells in decidua parietalis and basalis, but 233 not in the villous tissue, comparing placentae from PWLWH with PWNLHIV. The proportion of CD8+ 234 T cells was significantly increased (Figure 2A) in all three placental compartments resulting in 235 significantly lower CD4:CD8 T cell ratios in the three placental tissues from PWLWH (Figure 2B). 236 Notably, the inverted CD4:CD8 ratio in villous tissue was due to the increased CD8+ T cells in the 237 villous tissue. The inverted CD4:CD8 ration was partially reflected in cord blood from HEU (Figures 238 2B). No differences were identified in T cell proportions when stratified by the different ART 239 regimens (Supplementary Figure 2).

12

241 Maternal absolute peripheral blood CD4 T cell counts, measured pre-ART at a median of 28 weeks' 242 gestation, positively correlated with the proportion of CD4+ T cells in the decidua and negatively 243 correlated with the proportion of CD8+ T cells in decidua and villous tissue (Figure 2C and D). A 244 similar trend, without significance, was observed in cord blood. Thus, the inverted placental tissue 245 CD4:CD8+ T cell ratios appeared to reflect the maternal peripheral immune status but was mirrored 246 to a lesser extent in the cord blood of HEU. This correlation was temporally dissociated, where 247 correlations were made between blood measured at 28 weeks and placentae measured at 38-40 248 weeks of gestation, suggesting that inverted T cell ratios persisted throughout pregnancy.

249

250 Maternal viral load prior to ART initiation correlates with placental, but not cord blood, CD4+ and 251 CD8+T cell proportions.

252 Maternal plasma viraemia dropped precipitously over time from enrolment to delivery (-12 weeks 253 beforehand), where PWLWH receiving DTG decreased at a faster rate (Figure 3A)^[17]. As expected, 254 the enrolment plasma viraemia, ranging from $1.69 - 6.0 \log_{10}$ RNA copies/ml, significantly inversely 255 correlated with the absolute maternal peripheral blood CD4+ T cell count determined pre-ART, at 256 enrolment (Figure 3B). Interestingly, pre-ART viremia also showed a significant negative correlation 257 with proportions of CD4+ T cells in the decidua parietalis and basalis (Figure 3C) and a positive 258 correlation with CD8+ T cells in the decidua parietalis, basalis and villous tissue at delivery (Figure 259 3D). The association between maternal viral loads over time and the proportions of decidual CD4+ 260 and CD8+ T cells were maintained at -8 weeks and -4 weeks before delivery for CD4+ T cells 261 (Supplementary Figure 3) and up to -8 weeks before delivery for CD8+ T cells (Supplementary Figure 262 4). Maternal viremia did not correlate with the proportion of T cells in the cord blood (Figure 3C and 263 3D), suggesting that maternal VL (pre- and post-ART initiation) can influence the homeostatic 264 balance of T cells in the placenta, but not in the "newborn" immune compartment.

265

13

267 Immunohistochemistry confirms anatomical location and fetal origin of CD8+ T cells in villous tissue. 268 Analysis of placental villi from 13 PWLWH and 3 PWNLHIV controls showed the presence of CD8+ 269 cells in the fetal capillaries (Figure 4A). The numbers of CD8+ T cells positively correlated with pre-270 ART maternal viremia (Figure 4B), confirming the flow cytometric analysis (Figures 2A, 3D). Using 271 FISH to detect X and Y chromosomes in cells located within the villi from 5 placentae with male 272 births, we confirmed the presence of male (fetal) cells in fetal capillaries (Figure 4C). Thus the 273 immunohistochemistry analysis confirms the anatomical location and fetal origin of the increased 274 proportions of CD8+ T cells in villous tissue. The fetal (male) origin of the CD8+ T cells in placental 275 villi is consistent with the absence of VUE, a lesion that is characterized by maternal immune 276 infiltrates[20,28].

277

HIV exposure increases differentiation of CD8+ T cells in placental villi and fetal cord blood, but not in
the maternal placental compartments.

280 CD45RA and CD28 was used to identify the proportions of naïve (CD45RA+CD28+), early 281 differentiated (ED, CD45RA-CD28+), late differentiated (LD, CD45RA-CD28-) and terminally 282 differentiated (TD, CD45RA+CD28-) memory CD4+ and CD8+ T cells from villous tissue and matching 283 cord blood (Figure 5A). We observed significantly lower proportions of naïve CD8+ T cells and 284 significantly higher proportions of LD CD8+ T cells in villous tissue and cord blood of HEU compared 285 to HUU (Figure 5B). The CD4+ T cells in the villous tissue were predominantly of a naïve and ED 286 phenotype while the cord blood cells were predominantly naïve. There were no significant 287 differences in CD4+ T cell differentiation state based on HIV-exposure (Supplementary Figure 5). In 288 addition, no significant differences in the stage of CD4+ and CD8+ T cell differentiation in decidua 289 parietalis and decidua basalis was observed between the HIV groups (Supplementary Figure 6). Thus, 290 the increased differentiation state of CD8+ T cells is confined to the fetal placental and fetal cord 291 blood compartments and not observed in the maternal placental compartments. Interestingly, there

14

was no correlation between maternal pre-ART VL and memory stage of CD8+ T cells in placental

293 villous tissue and cord blood (data not shown).

15

295 Discussion

296 We present data from a unique cohort of PWLWH who initiated ART late in pregnancy and show that 297 maternal HIV infection has a clear impact on T cell subsets in the decidua, villous tissue and cord 298 blood. As the decidua and decidual immune cells are of maternal origin, it may not be surprising to 299 find such a footprint[29]. Maternal HIV infection likely affects and kills maternal decidual CD4+ T 300 cells and fewer peripheral blood T cells may traffic to decidual tissue; chemokine gradients have 301 been shown to play a key role in the trafficking of maternal T cells into the decidua during 302 pregnancy[30]. We show that in contrast to the decidua, the inverted CD4:CD8 ratio in the fetal 303 villous tissue was largely due to an increased proportion of CD8+ T cells and not, as observed in the 304 other tissues, due to a decrease in CD4+ T cells. These CD8+ T cells were of an early-late 305 differentiated phenotype, suggestive of previous antigen experience[31,32].

306

307 The human placenta has two circulatory compartments: the utero-placental unit for the trafficking 308 of maternal blood and the feto-placental unit for the fetal blood circulation[33,34]. Approximately 309 40% of the total fetal-placental blood volume exists as a reservoir in the placenta[34]. The cells we 310 characterised in the villous tissue and cord blood are from the feto-placental unit and these villous 311 tissue resident cells are likely predominantly from the placental reservoir. A key question is whether 312 the increased CD8+T cell differentiation in placental villi and cord blood is due to direct exposure to 313 HIV antigens, presence of other pathogens in placental or fetal compartments (e.g. CMV) or 314 increased levels of other non-infectious inflammatory cues in placentae of PWLWH. There is 315 evidence that despite separation of fetal and maternal circulations, viral particles, structural and 316 core HIV proteins have been shown to cross the placental barrier in the absence of fetal infection 317 leading to altered immune profiles in HEU infants[35,36]. A number of studies have also described 318 HIV-specific T cell responses in HEU infants, postulated to have been primed by exposure to HIV 319 antigens in utero[11,37,38]. The magnitude of these responses is greatest soon after birth but are 320 not detected in older HEU children, suggesting that in the absence of continuous exposure these

16

responses wane[10,38]. The lower proportion of naïve cells and increased memory T cells reflected in villous tissue and cord blood mirror previous studies; HEU infants have been shown to have reduced CD4+ T cell numbers and increased CD8+ T cells compared to HUU infants at birth[39,40]. HEU infants have also been shown to have lower naïve cells thought to be due to thymic involution and frequent stimulation and expansion of the antigen-specific T cells in an effort to regenerate the T cell pool[41–43]. Whether the same findings would be recapitulated in PWLHIV with preconception suppressed viral loads is unknown.

328

329 Interestingly the elevated proportions of CD8+ T cells found embedded in the placental villous tissue 330 from PWLHIV were shown to be sequestered within the fetal capillaries. Furthermore, these CD8+ T 331 cells within villous tissue were proportional to maternal viremia. The absence of overt VUE 332 corroborates the finding that expanded CD8+ T cell fractions are of fetal and not maternal origin. 333 Previous studies have suggested that the presence of T cells in the villi during normal pregnancy 334 reflect VUE[20]. However, there is emerging evidence, using IHC staining of villi sections from early 335 elective termination placentae, of the presence of CD45+ $\alpha\beta$ T cells, although these cells were 336 undetectable at term[44]. In a separate study, using single cell transcriptomic analysis in placentae 337 from women with or without preterm labour, where there were no reported maternal infections, 338 and villous tissue was shown to contain a mixture of fetal and maternal immune cells[45]. We 339 cannot discount the possibility that there was also a mix of maternal and fetal CD8+ T cells in 340 placental villi in our study.

341

Of particular note, women were ART naïve during the first and second trimester and it is likely that prolonged HIV exposure may have contributed to altered placental development and the significantly lower placental weight observed. Interestingly, all cases of maternal vascular malperfusion (MVM) were reported in placentae from HIV-infected women and possibly reflects placental injury affecting maternal vasculature and perfusion and increasing the risk of an adverse

17

 ART, an incidence of about 27% overall, similar to Kalk <i>et al.</i> [7,46]. It is likely that HIV and/or ART exposure alters factors involved in vascular development, resulting in placental insufficiency and increased risk of adverse birth outcomes[47]. In conclusion, we provide evidence that <i>in utero</i> exposure to HIV results in an altered immune footprint in both the utero-placental and feto-placental compartments. Despite the initiation of ART in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Our data suggests that the placenta may be a causal link between maternal and neonatal T cell perturbations previously observed in HEU newborns. 	347	birth outcome[26]. We have previously reported on MVM in placentae from PLWHIV on long-term
 increased risk of adverse birth outcomes[47]. In conclusion, we provide evidence that <i>in utero</i> exposure to HIV results in an altered immune footprint in both the utero-placental and feto-placental compartments. Despite the initiation of ART in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Our data suggests that the placenta may be a causal link between 	348	ART, an incidence of about 27% overall, similar to Kalk et al. [7,46]. It is likely that HIV and/or ART
In conclusion, we provide evidence that <i>in utero</i> exposure to HIV results in an altered immune footprint in both the utero-placental and feto-placental compartments. Despite the initiation of ART in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Our data suggests that the placenta may be a causal link between	349	exposure alters factors involved in vascular development, resulting in placental insufficiency and
In conclusion, we provide evidence that <i>in utero</i> exposure to HIV results in an altered immune footprint in both the utero-placental and feto-placental compartments. Despite the initiation of ART in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Our data suggests that the placenta may be a causal link between	350	increased risk of adverse birth outcomes[47].
footprint in both the utero-placental and feto-placental compartments. Despite the initiation of ART in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Our data suggests that the placenta may be a causal link between	351	
in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Our data suggests that the placenta may be a causal link between	352	In conclusion, we provide evidence that in utero exposure to HIV results in an altered immune
delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Our data suggests that the placenta may be a causal link between	353	footprint in both the utero-placental and feto-placental compartments. Despite the initiation of ART
356 degree in the cord blood. Our data suggests that the placenta may be a causal link between	354	in the third trimester, resulting in either full or partial maternal viral suppression by the time of
	355	delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser
357 maternal and neonatal T cell perturbations previously observed in HEU newborns.	356	degree in the cord blood. Our data suggests that the placenta may be a causal link between
	357	maternal and neonatal T cell perturbations previously observed in HEU newborns.

18

359 Author contributions

- 360 NMI, ML, SK, LM, HBJ, CMG: Conceptualization and design of the study
- 361 NMI, TT: Panel design, sample preparation and development of methods
- 362 KP: Histopathology scoring and interpretation
- 363 NMI, TRM and SD: Statistical analysis
- 364 NMI, TT, KP, TM, LM, EAE, RC, HBJ, CMG: Writing the manuscript

365

366 Funding

- 367 This research was supported by a Fellowship to NMI from the AXA Research Fund, Paris. The content
- 368 is solely the responsibility of the authors and does not necessarily represent the official views of
- 369 those of the AXA Research Fund. The research is part of the DOLPHIN-2 clinical trial sponsored by
- 370 UNITAID (ClinicalTrials.gov NCT03249181).

371

372 Acknowledgments

- 373 We wish to thank all the study participants in this study; all the members of the DOLPHIN-2 clinical
- 374 trial and INFANT placenta study. We also wish to thank Nonzwakazi Bangani, Goitseone Thamae,
- 375 Michelle Barboure, Berenice Alinde and Lizette Fick for their expert assistance in sample processing
- and Dr Amsha Ramburan for capturing the FISH images.

377

378

19

380 Figure Legends

381 Figure 1: Lymphocyte isolation from the human placenta

382 Stepwise isolation of lymphocytes from the human placenta decidua parietalis (DP), decidua basalis (DB) and 383 villous tissue (VT): (1) dissection of the whole placenta; (2) multiple rounds of maternal blood rinsing to avoid 384 contamination followed by enzymatic digestion of each dissected tissue; (3) lymphocyte separation obtained 385 by Percoll density centrifugation; (4) cryopreservation of fixed cells and immunophenotyping using flow 386 cytometry.

387

388 Figure 2: Proportions of T cells in the placenta and cord blood

389 (A) Box plots (showing medians and interquartile ranges) of CD3+CD4+CD8- T cells and CD3+CD4-CD8+ T cell 390 proportions isolated from the decidua parietalis, decidua basalis, villous tissue and cord blood from Pregnant 391 Women not living with HIV (PWNLHIV) and Pregnant Women living with HIV (PWLWH) and HIV unexposed 392 uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. (B) Box plots (showing medians and 393 interquartile ranges) of CD4:CD8 T cell ratios in the decidua parietalis, decidua basalis, villous tissue and cord 394 blood from Pregnant Women not living with HIV (PWNLHIV) and Pregnant Women living with HIV (PWLWH) 395 and HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. Tests of significance 396 were performed using the Mann-Whitney U test. (C) Correlation plots between the absolute maternal CD4 397 count at 28 weeks' gestation prior to ART initiation and the proportion of CD4+ T cells isolated from the 398 decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman 399 rank test and the grey shaded areas represent the 95% confidence intervals. (D) Correlation plots between the 400 absolute maternal CD4 count at 28 weeks' gestation prior to ART initiation and the proportion of CD8+T cells 401 isolated from the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed 402 using the Spearman rank test and the grey shaded areas represent the 95% confidence intervals.

403

404 Figure 3: Proportions of CD4+ and CD8+ T cells in the placenta and maternal viral load

405 (A) Line plot depicting participant viral load trajectories over time at enrolment and ART initiation (VLV1, 12
406 weeks before delivery), one week after ART initiation (VLV2, 8 weeks before delivery), four weeks after ART
407 initiation (VLV3, 4 weeks before delivery), thirty-six weeks' GA (VLV4, 2 weeks before delivery) and +/- 14 days
408 after delivery (VLV5, +/- 2 weeks after delivery). The women were randomised to receive efavirenz (EFV + TDF

20

409 + 3TC) (denoted in black) and dolutegravir (DTG + TDF + 3TC) (denoted in blue). (B) Correlation plot between 410 maternal systemic absolute CD4 counts at enrolment prior to ART initiation with maternal viral load at 411 enrolment and ART initiation (28 weeks GA). Statistical analysis was performed using the Spearman rank test 412 and the grey shaded area represents the 95% confidence intervals. (C) Correlation plots between CD4+ T cell 413 proportions in the placenta and maternal viral load at enrolment and ART initiation (28 weeks GA) in the 414 decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman 415 rank test and the grev shaded area represents the 95% confidence intervals. (D) Correlation plots between 416 CD8+ T cell proportions in the placenta and maternal viral load at enrolment and ART initiation (28 weeks GA) 417 in the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the 418 Spearman rank test and the grey shaded area represents the 95% confidence intervals.

419

420 Figure 4: Anatomical location of CD8+ T cells in the villous tissue

(A) Representative immunohistochemical stained images of CD8+ T cells in villous tissue sections denoted in brown dots and black arrows in the villi of placentae from HIV-infected and –uninfected mothers (40x magnification). (B) Correlation plot between the density of tissue-bound CD8+ T cells in the villi and maternal viral load at ART initiation (pre-ART). Statistical analysis was performed using the Spearman rank test and the black curved lines represent the 95% confidence intervals. (C) Representative Fluorescence in situ Hybridization (FISH) images of lymphocytes (white arrows) in the villous tissue from placentas from male infants. The X chromosome is denoted in green and Y chromosome denoted in red (digitally scanned slides).

428

429 Figure 5: Memory phenotype of CD4 and CD8 T cells in the Villous Tissue

(A) Representative flow cytometry contour plots of Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) CD4+ T cells and CD8+ T cells in the villous tissue (VT; upper panel) of placentae from PWNLHIV and PWLWH and cord blood from HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU). (B) Box plots (showing medians and interquartile ranges) of CD8+ Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) T cells in the villous tissue and cord blood from HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU). Tests of significance were performed using the Mann-Whitney U test.

21

438

439 Supplementary Figures

440 Supplementary Figure 1: Gating strategy to delineate CD3+ T cells

- 441 Representative flow cytometry dot plots depicting the gating strategy to delineate CD4+ and CD8+ T cells
- 442 gated from a live CD45+ CD14- CD3+ population in the placenta.
- 443

444 Supplementary Figure 2: Proportions of CD3+ T cells in the placenta and cord blood by ART group

- Box plots (showing medians and interquartile ranges) of (A) CD4+ and (B) CD8+ T cells in the decidua parietalis
- 446 (DPar), decidua basalis (DBas), villous tissue (VTiss) and cord blood (Cblood) from HIV-uninfected (MHIV neg)
- 447 and infected mothers on efavirenz (EFV) or dolutegravir (DTG) and HIV unexposed and uninfected (HUU) and
- 448 HIV exposed uninfected (HEU) cord bloods. Tests of significance were performed using the Kruskal-Wallis test.
- 449

450 Supplementary Figure 3: Proportions of CD4+ T cells in the placenta, cord blood and maternal viral load

- 451 Correlation plots between CD4+T cell proportions in the placenta and cord blood and maternal viral load one 452 week after ART initiation (visit 2, 8 weeks before delivery), four weeks after ART initiation (visit 3, 4 weeks
- 453 before delivery) and thirty-six weeks' GA (visit 4, 2 weeks before delivery) in the decidua parietalis, basalis,
- 454 villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey
- 455 shaded area represents the 95% confidence intervals.

456

457 Supplementary Figure 4: Proportions of CD8+ T cells in the placenta, cord blood and maternal viral load

Correlation plots between CD8+T cell proportions in the placenta and cord blood and maternal viral load one week after ART initiation (visit 2, 8 weeks before delivery), four weeks after ART initiation (visit 3, 4 weeks before delivery) and thirty-six weeks' GA (visit 4, 2 weeks before delivery) in the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded area represents the 95% confidence intervals.

463

464 Supplementary Figure 5: Memory differentiation of CD4+ T cells in the villous tissue and cord blood

465 Box plots (showing medians and interquartile ranges) of CD4+ Naïve, Early differentiated (ED), Late 466 differentiated (LD) and Terminally differentiated (TD) T cells in the villous tissue (VT; upper panel) and cord

22

467	blood (CB; lower panel) from HIV-uninfected (MHIV neg) and infected mothers (MHIV pos) and HIV unexposed
468	and uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. Tests of significance were performed
469	using the Mann-Whitney <i>U</i> test.
470	
471	Supplementary Figure 6: Memory differentiation of CD4 and CD8 T cells in the decidua parietalis and
472	decidua basalis
473	Representative flow cytometry contour plots of Naïve, Early differentiated (ED), Late differentiated (LD) and
474	Terminally differentiated (TD) CD4+ T cells (upper panel) and CD8+ T cells (lower panel) in the decidua
475	parietalis and basalis.
476	
477	Supplementary Figure 7: Memory phenotype of CD4 T cells in the Villous Tissue
478	Box plots (showing medians and interquartile ranges) of CD4+ and CD8+ Naïve, Early differentiated (ED), Late
479	differentiated (LD) and Terminally differentiated (TD) T cells in the decidua parietalis and basalis from HIV-
480	uninfected (MHIV neg) and infected mothers (MHIV pos). Tests of significance were performed using the
481	Mann-Whitney U test.

483 References

- 484 1. Okoye AA, Picker LJ. CD4 + T-cell depletion in HIV infection: mechanisms of immunological
- 485 failure. Immunol Rev [Internet]. 2013 Jul;254(1):54–64. Available from:
- 486 http://doi.wiley.com/10.1111/imr.12066
- 487 2. Demers KR, Makedonas G, Buggert M, et al. Temporal Dynamics of CD8+ T Cell Effector
- 488 Responses during Primary HIV Infection. Douek DC, editor. PLOS Pathog [Internet]. 2016 Aug
- 489 3;12(8):e1005805. Available from: http://dx.plos.org/10.1371/journal.ppat.1005805
- 490 3. Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral Therapy in
- 491 HIV. Curr HIV/AIDS Rep [Internet]. 2017;14(3):93–100. Available from:
- 492 http://www.ncbi.nlm.nih.gov/pubmed/28434169
- 493 4. Okhai H, Vivancos-Gallego MJ, Hill T, Sabin CA. CD4+:CD8+ T Cell Ratio Normalization and the
- 494 Development of AIDS Events in People with HIV Starting Antiretroviral Therapy. AIDS Res
- 495 Hum Retroviruses [Internet]. 2020 Oct 1;36(10):808–16. Available from:
- 496 https://www.liebertpub.com/doi/10.1089/aid.2020.0106
- 497 5. Cocker ATH, Shah NM, Raj I, et al. Pregnancy Gestation Impacts on HIV-1-Specific Granzyme B
- 498 Response and Central Memory CD4 T Cells. Front Immunol [Internet]. 2020 Feb 11;11.
- 499 Available from: https://www.frontiersin.org/article/10.3389/fimmu.2020.00153/full
- 500 6. Heffron R, Donnell D, Kiarie J, et al. A Prospective Study of the Effect of Pregnancy on CD4
- 501 Counts and Plasma HIV-1 RNA Concentrations of Antiretroviral-Naive HIV-1–Infected Women.
- 502 JAIDS J Acquir Immune Defic Syndr [Internet]. 2014 Feb;65(2):231–6. Available from:
- 503 http://journals.lww.com/00126334-201402010-00016
- 504 7. Kalk E, Schubert P, Bettinger JA, et al. Placental pathology in HIV infection at term: a
- 505 comparison with HIV-uninfected women. Trop Med Int Health [Internet]. 2017;22(5):604–13.
- 506 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28214384
- 507 8. Mwanyumba F, Gaillard P, Inion I, et al. Placental Inflammation and Perinatal Transmission of
- 508 HIV-1. JAIDS J Acquir Immune Defic Syndr [Internet]. 2002 Mar;29(3):262–9. Available from:

24

509 http://journals.lww.com/00126334-200203010-00006

- 510 9. Ono E, Santos AMN dos, Succi RC de M, et al. Imbalance of naive and memory T lymphocytes
- 511 with sustained high cellular activation during the first year of life from uninfected children
- 512 born to HIV-1-infected mothers on HAART. Brazilian J Med Biol Res [Internet]. 2008
- 513 Aug;41(8):700–8. Available from:
- 514 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-
- 515 879X2008000800011&lng=en&tlng=en
- 516 10. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation abnormalities in uninfected
- 517 newborns and children with vertical exposure to HIV. Blood [Internet]. 2000 Dec
- 518 1;96(12):3866–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11090071
- 519 11. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed
- 520 uninfected children: a growing population with a vulnerable immune system? Clin Exp
- 521 Immunol [Internet]. 2014 Apr;176(1):11–22. Available from:
- 522 http://www.ncbi.nlm.nih.gov/pubmed/24325737
- 523 12. Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the global population of
- 524 children who are HIV-exposed and uninfected, 2000–18: a modelling study. Lancet Glob Heal
- 525 [Internet]. 2020 Jan;8(1):e67–75. Available from:
- 526 https://linkinghub.elsevier.com/retrieve/pii/S2214109X19304486
- 527 13. Williams PJ, Searle RF, Robson SC, Innes BA, Bulmer JN. Decidual leucocyte populations in
- 528 early to late gestation normal human pregnancy. J Reprod Immunol [Internet]. 2009
- 529 Oct;82(1):24–31. Available from:
- 530 https://linkinghub.elsevier.com/retrieve/pii/S0165037809004100
- 531 14. Nancy P, Erlebacher A. T cell behavior at the maternal-fetal interface. Int J Dev Biol [Internet].
- 532 2014;58(2–4):189–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25023685
- 533 15. Tilburgs T, Schonkeren D, Eikmans M, et al. Human Decidual Tissue Contains Differentiated
- 534 CD8 + Effector-Memory T Cells with Unique Properties. J Immunol [Internet]. 2010 Oct

535		1;185(7):4470–7. Available from:
536		http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.0903597
537	16.	Tilburgs T, Strominger JL. CD8+ effector T cells at the fetal-maternal interface, balancing fetal
538		tolerance and antiviral immunity. Am J Reprod Immunol [Internet]. 2013 Apr;69(4):395–407.
539		Available from: http://www.ncbi.nlm.nih.gov/pubmed/23432707
540	17.	Mjösberg J, Berg G, Jenmalm MC, Ernerudh J. FOXP3+ regulatory T cells and T helper 1, T
541		helper 2, and T helper 17 cells in human early pregnancy decidua. Biol Reprod [Internet].
542		2010 Apr;82(4):698–705. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20018909
543	18.	Tilburgs T, Roelen DL, van der Mast BJ, et al. Evidence for a selective migration of fetus-
544		specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in
545		human pregnancy. J Immunol [Internet]. 2008 Apr 15;180(8):5737–45. Available from:
546		http://www.ncbi.nlm.nih.gov/pubmed/18390759
547	19.	Redline RW. Villitis of unknown etiology: noninfectious chronic villitis in the placenta. Hum
548		Pathol [Internet]. 2007 Oct;38(10):1439–46. Available from:
549		http://www.ncbi.nlm.nih.gov/pubmed/17889674
550	20.	Tamblyn JA, Lissauer DM, Powell R, Cox P, Kilby MD. The immunological basis of villitis of
551		unknown etiology – Review. Placenta [Internet]. 2013 Oct;34(10):846–55. Available from:
552		https://linkinghub.elsevier.com/retrieve/pii/S0143400413005894
553	21.	Kintu K, Malaba TR, Nakibuka J, et al. Dolutegravir versus efavirenz in women starting HIV
554		therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV
555		[Internet]. 2020 May;7(5):e332–9. Available from:
556		https://linkinghub.elsevier.com/retrieve/pii/S2352301820300503
557	22.	Tilburgs T, Crespo ÂC, van der Zwan A, et al. Human HLA-G+ extravillous trophoblasts:
558		Immune-activating cells that interact with decidual leukocytes. Proc Natl Acad Sci [Internet].
559		2015 Jun 9;112(23):7219–24. Available from:
560		http://www.pnas.org/lookup/doi/10.1073/pnas.1507977112

- 561 23. Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental Lesions: Amsterdam
- 562 Placental Workshop Group Consensus Statement. Arch Pathol Lab Med [Internet]. 2016
- 563 Jul;140(7):698–713. Available from:
- 564 http://www.archivesofpathology.org/doi/10.5858/arpa.2015-0225-CC
- 565 24. Kallapur S, Presicce P, Rueda C, Jobe A, Chougnet C. Fetal Immune Response to
- 566 Chorioamnionitis. Semin Reprod Med [Internet]. 2014 Jan 3;32(01):056–67. Available from:
- 567 http://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1361823
- 568 25. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis
- and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol
- 570 [Internet]. 2015 Oct;213(4):S29–52. Available from:
- 571 https://linkinghub.elsevier.com/retrieve/pii/S0002937815009102
- 572 26. Ernst LM. Maternal vascular malperfusion of the placental bed. APMIS [Internet]. 2018
- 573 Jul;126(7):551–60. Available from: http://doi.wiley.com/10.1111/apm.12833
- 574 27. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna,
- 575 Austria: R Foundation for Statistical Computing; 2020. Available from: https://www.r-
- 576 project.org/
- 577 28. Enninga EAL, Raber P, Quinton RA, et al. Maternal T Cells in the Human Placental Villi Support
- 578 an Allograft Response during Noninfectious Villitis. J Immunol [Internet]. 2020 Jun
- 579 1;204(11):2931–9. Available from:
- 580 http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1901297
- 581 29. Ander SE, Diamond MS, Coyne CB. Immune responses at the maternal-fetal interface. Sci
- 582 Immunol [Internet]. 2019 Jan 11;4(31):eaat6114. Available from:
- 583 http://immunology.sciencemag.org/lookup/doi/10.1126/sciimmunol.aat6114
- 584 30. Huang Y, Zhu X-Y, Du M-R, Li D-J. Human trophoblasts recruited T lymphocytes and
- 585 monocytes into decidua by secretion of chemokine CXCL16 and interaction with CXCR6 in the
- 586 first-trimester pregnancy. J Immunol [Internet]. 2008 Feb 15;180(4):2367–75. Available from:

587		http://www.ncbi.nlm.nih.gov/pubmed/18250446
588	31.	Tilburgs T, Strominger JL. CD8+ Effector T Cells at the Fetal-Maternal Interface, Balancing
589		Fetal Tolerance and Antiviral Immunity. Am J Reprod Immunol [Internet]. 2013
590		Apr;69(4):395–407. Available from: http://doi.wiley.com/10.1111/aji.12094
591	32.	White JT, Cross EW, Kedl RM. Antigen-inexperienced memory CD8+ T cells: where they come
592		from and why we need them. Nat Rev Immunol [Internet]. 2017 Jun;17(6):391–400. Available
593		from: http://www.ncbi.nlm.nih.gov/pubmed/28480897
594	33.	Dawe GS, Tan XW, Xiao Z-C. Cell migration from baby to mother. Cell Adh Migr [Internet].
595		2007;1(1):19–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19262088
596	34.	Acharya G, Sonesson S-E, Flo K, Räsänen J, Odibo A. Hemodynamic aspects of normal human
597		feto-placental (umbilical) circulation. Acta Obstet Gynecol Scand [Internet]. 2016
598		Jun;95(6):672–82. Available from: http://doi.wiley.com/10.1111/aogs.12919
599	35.	Nielsen SD, Jeppesen DL, Kolte L, et al. Impaired progenitor cell function in HIV-negative
600		infants of HIV-positive mothers results in decreased thymic output and low CD4 counts.
601		Blood [Internet]. 2001 Jul 15;98(2):398–404. Available from:
602		http://www.ncbi.nlm.nih.gov/pubmed/11435309
603	36.	Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in
604		the era of paediatric HIV elimination. Lancet Infect Dis [Internet]. 2016 Jun;16(6):e92–107.
605		Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309916000554
606	37.	Kuhn L, Coutsoudis A, Moodley D, et al. T-helper cell responses to HIV envelope peptides in
607		cord blood: protection against intrapartum and breast-feeding transmission. AIDS [Internet].
608		2001 Jan 5;15(1):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11192849
609	38.	Holditch SJ, Eriksson EM, Tarosso LF, et al. Decay kinetics of HIV-1 specific T cell responses in
610		vertically HIV-1 exposed seronegative infants. Front Immunol [Internet]. 2011;2:94. Available
611		from: http://www.ncbi.nlm.nih.gov/pubmed/22566883
612	39.	Huo Y, Patel K, Scott GB, et al. Lymphocyte subsets in HIV-exposed uninfected infants and

- 613 HIV-unexposed uninfected infants. J Allergy Clin Immunol [Internet]. 2017 Aug;140(2):605-
- 608.e3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S009167491730338X
- 615 40. Borges-Almeida E, Milanez HM, Vilela MMS, et al. The impact of maternal HIV infection on
- 616 cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC
- 617 Infect Dis [Internet]. 2011 Dec 3;11(1):38. Available from:
- 618 http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-11-38
- 619 41. Mansoor N, Abel B, Scriba TJ, et al. Significantly skewed memory CD8+ T cell subsets in HIV-1
- 620 infected infants during the first year of life. Clin Immunol [Internet]. 2009 Mar;130(3):280–9.
- 621 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18996749
- 622 42. Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence during aging. Curr Opin
- 623 Immunol [Internet]. 2005 Oct;17(5):480–5. Available from:
- 624 http://www.ncbi.nlm.nih.gov/pubmed/16098721
- 625 43. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat
- 626 Immunol [Internet]. 2004 Feb 28;5(2):133–9. Available from:
- 627 http://www.nature.com/articles/ni1033
- 628 44. Bonney EA, Pudney J, Anderson DJ, Hill JA. Gamma-Delta T Cells in Midgestation Human
- 629 Placental Villi. Gynecol Obstet Invest [Internet]. 2000;50(3):153–7. Available from:
- 630 https://www.karger.com/Article/FullText/10315
- 631 45. Pique-Regi R, Romero R, Tarca AL, et al. Single cell transcriptional signatures of the human
- 632 placenta in term and preterm parturition. Elife [Internet]. 2019 Dec 12;8. Available from:
- 633 https://elifesciences.org/articles/52004
- 634 46. Ikumi NM, Malaba TR, Komala P, et al. Associating antiretroviral therapy initiated before or
- 635 during pregnancy with placenta pathology in HIV infected women. medRixv. 2020;
- 636 47. Weckman AM, Ngai M, Wright J, McDonald CR, Kain KC. The Impact of Infection in Pregnancy
- on Placental Vascular Development and Adverse Birth Outcomes. Front Microbiol [Internet].
- 638 2019 Aug 22;10. Available from:

29

639 https://www.frontiersin.org/article/10.3389/fmicb.2019.01924/full

641 Table 1: Maternal and infant characteristics


	PWNLHIV N=9	PWLWH N=21	P-Value
Age, years			1.0
≤24	1 (11.1)	2 (9.5)	
25-29	5 (55.6)	11 (52.4)	
≥30	3 (33.3)	8 (38.1)	
Median (IQR)	29 (25 - 31)	29 (26 - 30)	
Median gestation at enrolment	30 (26 - 32)	28 (28 - 31)	0.6
Gravidity			0.003
1	5 (55.6)	1 (4.8)	
2	3 (33.3)	7 (33.3)	
≥3	1 (11.1)	13 (61.9)	
Median (IQR)	1 (1 - 2)	3 (2 - 3)	
Infant Characteristics			
Sex			1.0
Female	6 (66.7)	12 (57.1)	
Male	3 (33.3)	6 (28.6)	
Missing	0 (0)	3 (14.3)	
Median gestation at delivery (completed weeks)	40 (40)	39 (38 - 39)	0.003
Birthweight in grams, Median (IQR)	3420 (3420 - 4000)	3305 (3010 - 3570)	0.07

642

644 Table 2: Placental characteristics and pathology at delivery

	PWNLHIV N=9	PWLWH N=21	P-Value
Placental basal plate weight (g), median (IQR)	468 (426 - 533)	394 (343 – 469)	0.02
Placental weight (g)			0.03
Small (<10 th percentile)	0 (0)	8 (38.1)	
Appropriate (10 - 90 th percentile)	9 (100.0)	12 (57.1)	
Large (>90 th percentile)	0 (0)	0 (0)	
Missing	0 (0)	1 (4.8)	
Fetal-Placenta weight ratio			0.02
Small (<10 th percentile)	1 (11.1)	0 (0)	
Appropriate (10 - 90 th percentile)	8 (88.9)	11 (52.4)	
Large (>90 th percentile)	0 (0)	7 (33.3)	
Missing	0 (0)	3 (14.9)	
Placenta greatest diameter (mm), median (IQR)	180 (172 - 210)	180 (170 - 199)	0.6
Placenta thickness (mm), median (IQR)	20 (15 -20)	25 (16.5 - 27.5)	0.2
Cord insertion			0.7
Central	3 (33.3)	3 (33.3)	
Off centre	5 (55.6)	12 (57.1)	
Margina	1 (11.1)	5 (23.8)	
Missing	0 (0)	1 (4.76)	
Meconium exposure			0.1
+	3 (33.3)	2 (9.5)	
-	6 (66.7)	19 (90.5)	
Chorioamnionitis			
Maternal Inflammatory Response			0.6
+	2 (22.2)	2 (9.5)	
-	7 (77.8)	19 (90.5)	
Fetal Inflammatory Response			0.6
+	2 (22.2)	3 (14.3)	
<u>-</u>	7 (77.8)	18 (85.7)	
Chronic Deciduitis			0.5
+	0 (0)	2 (9.5)	
<u>-</u>	9 (100)	19 (90.5)	
Maternal Vascular Malperfusion	× <i>i</i>		0.09
+	0 (0)	6 (28.6)	
-	9 (100)	15 (71.4)	
Villitis of Unknown Etiology	· ·		1.0
+	0 (0)	0 (0)	
<u>-</u>	9 (100)	21 (100)	

Figure 1



Monocytes/ Macrophages


Erythrocytes/ Granulocytes

Lymphocytes


Created in BioRender.com bio

FSC-A

Figure 2








Absolute maternal CD4 at 28 weeks' gestation prior to ART (cells/mm³)

Figure 3








Figure 4




Figure 5

